Chiesi Global Rare Diseases Announces FDA Approval of Ferriprox (deferiprone) for Treatment of Transfusional Iron Overload due to Sickle Cell Disease

Article Link: Chiesi Global Rare Diseases Announces FDA Approval of Ferriprox (deferiprone) for Treatment of Transfusional Iron Overload due to Sickle Cell Disease

May 1, 2021

Approval is based on demonstrated reduction in liver iron concentration
Expanded indications for patients with sickle cell disease or other anemias, as well as thalassemia –

BOSTON, May 1, 2021 /PRNewswire/ — Chiesi Global Rare…

Source: FDA New Drug Approvals